Loading…
Aditxt, Inc. is projected to decline to $0.1829 by 2027, a -11% move from its current price of $0.2049. ADTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.18 | $0.2052 | $0.2338 | +0.13% |
| May 30 | $0.1707 | $0.2054 | $0.2472 | +0.25% |
| May 31 | $0.164 | $0.2057 | $0.258 | +0.38% |
| Jun 1 | $0.1585 | $0.2059 | $0.2675 | +0.50% |
| Jun 2 | $0.1539 | $0.2062 | $0.2763 | +0.63% |
| Jun 3 | $0.1498 | $0.2065 | $0.2845 | +0.76% |
| Jun 4 | $0.1462 | $0.2067 | $0.2922 | +0.88% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.1462 | $0.2067 | $0.2922 | +0.88% |
| Week 2 | $0.1278 | $0.2085 | $0.3403 | +1.77% |
| Week 3 | $0.1155 | $0.2104 | $0.3832 | +2.67% |
| Week 4 | $0.1062 | $0.2122 | $0.4242 | +3.58% |
| Week 5 | $0.0987 | $0.2141 | $0.4644 | +4.49% |
| Week 6 | $0.0925 | $0.216 | $0.5044 | +5.42% |
| Week 7 | $0.0872 | $0.2179 | $0.5446 | +6.35% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.
It develops ADI-100 for skin grafting, psoriasis, and type-1 diabetes. In addition, the company provides Pearsanta that develops molecular tests based on the mitochondrial DNA (mtDNA) to develop tests for early detection of cancer; Mitomic targets mutations in mitochondrial DNA (mtDNA) to detect disease; Mitomic prostate test a blood-based assay that quantifies the level of the 3.4kb mtDNA deletion; and Mitomic endometriosis test, a blood-based assay that quantifies the level of one or more mtDNA deletions. Further, it offers Adivir for commercial development of products to address significant unmet needs in infectious disease and population health; and Adifem address critical unmet needs in women health.
The company has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc.
in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.
Aditxt, Inc. trades under the ticker ADTX and is categorized in Healthcare. The current price is $0.2049 with a market capitalization of $167.18K, and it holds a very low market cap with a wide price potential according to the stated forecasts.
The stock shows a neutral near-term stance based on the technical setup, with a 30-day trading range between $0.0852 and $0.493 and a near-term support at $0.205 and resistance at $12.07.
A major level 0.0% above — losing it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 5790.2% above — a clean break opens room to run.
A major ceiling 153809.2% above — clearing it would confirm fresh momentum.
Key ADTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.719 | Sell | $0.6577 | Sell |
| MA 10 | $1.25 | Sell | $1.33 | Sell |
| MA 20 | $2.58 | Sell | $3.70 | Sell |
| MA 50 | $12.06 | Sell | $100.65 | Sell |
| MA 100 | $80.11 | Sell | $94,429.83 | Sell |
| MA 200 | $5,783.44 | Sell | $40,562,319.30 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 13.17 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -116.86 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 1.28 | Buy |
| ROC (12) | -93.62 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -6.54 | Sell |
| Awesome (5,34) | -4.96 | Sell |
| Ultimate (7,14,28) | 0.66 | Buy |
| Momentum (10) | -2.09 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.14 | Buy |
| ADX (14) | 67.48 | Sell |
| ATR (14) | 0.74 | Info |
The 30-day technical picture is mixed but leans toward neutral sentiment. RSI14 is 10, indicating oversold conditions on a momentum basis, while the near-term trend is reflected in the vast gap between the SMA50 ($12.06) and the SMA200 ($5,783.44). The stock has a defined near-term support at $0.205 and a resistance at $12.07, with the 30-day range extending from $0.0852 to $0.493.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.2049 | $0.2049 | $0.2816 | 0% | Neutral | |
| $0.1316 | $0.1829 | $0.2749 | -11% | Neutral | |
| $0.1223 | $0.1803 | $0.2882 | -12% | Neutral | |
| $0.1024 | $0.159 | $0.2665 | -22% | Bearish | |
| $0.1036 | $0.1686 | $0.2939 | -18% | Bearish | |
| $0.1542 | $0.2621 | $0.4727 | +28% | Bullish | |
| $0.1455 | $0.2579 | $0.4793 | +26% | Bullish | |
| $0.1206 | $0.2226 | $0.4252 | +9% | Neutral | |
| $0.1197 | $0.2297 | $0.4497 | +12% | Neutral | |
| $0.0936 | $0.1868 | $0.3742 | -9% | Neutral | |
| $0.146 | $0.3245 | $0.7139 | +58% | Bullish | |
| $0.2787 | $0.6193 | $1.42 | +202% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.2049 | $0.2049 | $0.2433 | +0.00% |
| June 2026 | $0.1799 | $0.2158 | $0.2681 | +5.30% |
| July 2026 | $0.1884 | $0.2298 | $0.2929 | +6.49% |
| August 2026 | $0.1794 | $0.2217 | $0.2881 | -3.51% |
| September 2026 | $0.1703 | $0.2128 | $0.2809 | -4.00% |
| October 2026 | $0.1744 | $0.2202 | $0.2947 | +3.47% |
| November 2026 | $0.1724 | $0.2197 | $0.2976 | -0.25% |
| December 2026 | $0.1599 | $0.2056 | $0.2816 | -6.43% |
Click any year to see its month-by-month ADTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ADTX could reach as high as $0.2816, with a base case around $0.2049 and support toward $0.2049 — roughly 0% from $0.2049. Price action looks broadly range-bound.
Expect ADTX to range from $0.1316 to $0.2749 through 2027. The $0.1829 average target implies a -11% move from current prices. That is -11% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The ADTX price prediction for 2028 points to an average of $0.1803 (low $0.1223, high $0.2882) — a potential decline of -12% on today's $0.2049. Price action looks broadly range-bound.
In 2029, ADTX is projected to trade between $0.1024 and $0.2665, averaging $0.159 — a potential decline of -22% from today's $0.2049. That is -12% versus the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
Aditxt, Inc.'s 2030 outlook centres on $0.1686, within a $0.1036 to $0.2939 range. That is up +6% on the projected 2029 average. That marks a -18% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2031, ADTX could reach as high as $0.4727, with a base case around $0.2621 and support toward $0.1542 — roughly +28% from $0.2049. Buyers look set to stay in control over this stretch.
Expect ADTX to range from $0.1455 to $0.4793 through 2032. The $0.2579 average target implies a +26% move from current prices. That is -2% versus the projected 2031 average. Momentum favours further upside here.
The ADTX price prediction for 2033 points to an average of $0.2226 (low $0.1206, high $0.4252) — a potential gain of +9% on today's $0.2049. A consolidation phase looks the most probable path here.
In 2034, ADTX is projected to trade between $0.1197 and $0.4497, averaging $0.2297 — a potential gain of +12% from today's $0.2049. That is up +3% on the projected 2033 average. Price action looks broadly range-bound.
Aditxt, Inc.'s 2035 outlook centres on $0.1868, within a $0.0936 to $0.3742 range. That is -19% versus the projected 2034 average. That marks a -9% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, ADTX could reach as high as $0.7139, with a base case around $0.3245 and support toward $0.146 — roughly +58% from $0.2049. Momentum favours further upside here.
Expect ADTX to range from $0.2787 to $1.42 through 2050. The $0.6193 average target implies a +202% move from current prices. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADTX today (≈ 4,880.429478 ADTX) could be worth
$3,022.61
+$2,022.61 (+202%) by 2050 · US Dollar
Based on the average projected ADTX price of $0.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADTXwould be worth at today's price.
$1,000 invested in ADTX on May 27, 2025 (≈ 0.0241 ADTX) would be worth
$0
-$1,000 (-100.0%) today · 0.00× · US Dollar
Based on a ADTX entry price of $41,493.6 vs. today's $0.2049.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.4 | $146.36 | -85.4% |
| 1 month ago | $6.72 | $30.48 | -97.0% |
| 3 months ago | $103.46 | $1.98 | -99.8% |
| 6 months ago | $820.8 | $0.25 | -100.0% |
| 1 year ago | $41,493.6 | $0 | -100.0% |
| All time (5.0y) ago | $1,405,900,816,384 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADTX forecast.
Our base-case forecast reaches $0.41 around 2050.
Implied market cap at $0.41: $334.53K
The multi-year forecast shows a choppy but evolving path. For 2026 the min and avg are both $0.2049 with a max of $0.2816 and a neutral sentiment, implying little change in the near term. Bearish years appear in 2029 (avg $0.159, max $0.2665, ROI -22.4) and 2030 (avg $0.1686, max $0.2939, ROI -17.7).
The forecast turns bullish in 2031 (avg $0.2621, ROI 27.9) and 2032 (avg $0.2579, ROI 25.9). Further out, 2040 shows a bullish outlook with avg $0.3245 and ROI 58.4, and 2050 trades higher with avg $0.6193 and ROI 202.3, indicating substantial upside potential. The 2050 maximum is $1.42, underscoring the potential for meaningful upside by mid-century, even as earlier years present downside risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.1686 with a ROI of -17.7% (bearish). The max for 2030 is $0.2939 and the min is $0.1036.
Forecasts show a mix of outcomes: bearish years in 2029 and 2030 with negative ROIs, followed by bullish years in 2031 (ROI 27.9) and 2032 (ROI 25.9), then stronger upside in 2040 (ROI 58.4) and 2050 (ROI 202.3). These are estimates and not guarantees.
Yes. The forecast includes years with higher potential, including a 2050 max of $1.42, with an average around $0.6193 and an upside of 202.3%.
The 30-day range is $0.0852 to $0.493.
Current price is $0.2049 and market cap is $167.18K.
Aditxt, Inc. Community Discussion
0Share your Aditxt, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.